\
&
Contact us
\
&
Contact us
This was 10 months ago
LocationOnline
ProgrammesThe European Partnership for Personalised Medicine has just launched a new opportunity for start-ups, researchers and early-stage teams working on cutting-edge solutions in personalised medicine.
Translating breakthrough innovations in personalised medicine (PM) into commercialised solutions that directly benefit patients remains a critical challenge in the healthcare industry. The absence of tailored business support often hinders the translation of scientific advancements & discoveries into market-ready solutions.
The EP PerMed Venture Creation Programme offers guidance from experienced mentors, ensuring that each project receives support throughout its journey. In this webinar, EP PerMed will provide an overview of the programme, including its requirements, the application process, and the support available, offering key insights for those interested in applying.
More information and registration here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health Digital, Industry & Space Digital Europe
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
